CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.71% | 22.80% | 43.17% | 26.71% | 1.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.71% | 22.80% | 43.17% | 26.71% | 1.58% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -25.71% | 22.80% | 43.17% | 26.71% | 1.58% |
| SG&A Expenses | -21.12% | 21.59% | -28.15% | 16.73% | 13.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.58% | -5.07% | -24.98% | 26.05% | 19.57% |
| Operating Income | 84.78% | 94.06% | 3,017.33% | 31.64% | -152.45% |
| Income Before Tax | 98.60% | 70.43% | 893.60% | -0.31% | -496.41% |
| Income Tax Expenses | 23.53% | 26.53% | -94.20% | -97.84% | -- |
| Earnings from Continuing Operations | 97.64% | 70.58% | 2,155.20% | 91.71% | -501.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.64% | 70.58% | 2,155.20% | 91.71% | -501.10% |
| EBIT | 84.78% | 94.06% | 3,017.33% | 31.64% | -152.45% |
| EBITDA | 88.25% | 89.76% | 15,176.67% | 25.87% | -191.93% |
| EPS Basic | 98.44% | 60.62% | 2,036.89% | 81.67% | -372.39% |
| Normalized Basic EPS | 99.16% | 60.53% | 845.21% | -5.33% | -367.65% |
| EPS Diluted | 98.50% | 60.62% | 2,520.24% | 81.67% | -300.00% |
| Normalized Diluted EPS | 99.16% | 61.60% | 845.21% | -5.35% | -367.65% |
| Average Basic Shares Outstanding | 52.07% | 6.21% | 5.13% | 5.40% | 27.57% |
| Average Diluted Shares Outstanding | 52.07% | 5.47% | 5.13% | 5.20% | 27.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |